There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET [...]
We have all been ever increasingly aware of the weakness of our scanning technologies when it comes to both diagnosing prostate cancer and its recurrence. Given that about 1/3 of all primary treatments for prostate cancer will fail and the cancer will return it is vital that we improve our ability to detect prostate cancer [...]
According to a press release from the Decatur Memorial Hospital in Decatur Ill., after their having completed a clinical trial evaluating C-11 Choline PET CT and in men who have suffered a biochemical relapse of prostate cancer, they are now offering the C-11 Choline PET CT commercially. C-11 Choline uses an FDA approved tracer which, [...]
There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence [...]
According to an article in the Journal of Nuclear Medicine, researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT of the chest, abdomen and pelvis — to detect prostate-specific membrane antigen (PSMA), which is associated with prostate cancer metastases. [...]